Kirk Tanner, Ph.D.

Kirk is an oncology research leader with more than two decades of experience in discovery and development projects and programs resulting in multiple clinical candidate therapies and investigational new drugs. Kirk serves as the Chair of the Glioblastoma Drug Development Summit, the only devoted meeting for large pharma, biotech, and pioneering academics working to unite all stakeholders under a mutual and ambitious objective of accelerating the practical discovery, translation, and clinical development of safe, effective and deliverable therapies to treat glioblastoma. He has previously held roles as the Research Oncology Disease Area Expert and Senior Director at Vertex Pharmaceuticals, and as CSO of the National Brain Tumor Society’s research program. Kirk received his Ph.D. in chemistry from the University of California, San Diego, and did post-doctoral training at Oregon Health Sciences University.